Aug 2026· World journal of urology· Vol 44· 0 citations· 112 references
Medicine
TL;DR
The multifaceted regulatory networks of non-coding RNAs in renal cell carcinoma are delineated and their therapeutic relevance and translational potential are critically assessed to critically assess their therapeutic relevance and translational potential in precision oncology.
New emphasis is placed on emerging evidence demonstrating how immunophenotype-related lncRNAs regulate immune cell infiltration, immune checkpoint signaling, and the immunosuppressive glioblastoma microenvironment, highlighting their potential to improve patient stratification and guide immunotherapeutic approaches.
N. Elemam, Jana H. Sweillam, Youssef A. El-Sherif et al.· Frontiers in Immunology· 1 citation
This review systematically explores the molecular mechanisms underlying the interactions between non-coding RNAs and alternative splicing events, highlighting the role of this regulatory network in modulating the expression of oncogenes and tumor suppressor genes in HCC.
This review examines how different types of ncRNAs contribute to cancer initiation, progression, and treatment resistance, and assesses their potential as diagnostic markers, prognostic factors, and therapeutic targets.
Akanksha Samuel, G. Calin· Carcinogenesis· 0 citations
This review systematically summarize current advances in lncRNA-mediated regulation of cancer metastasis and drug resistance, with particular emphasis on their roles in oncogenic signaling cascades, transcriptional control, immune cell reprogramming, and metabolic remodeling.
Dong Liang, Jing-Wen Zheng, Zheng-Dan Gao et al.· Biochimica et biophysica act...· 0 citations
Current knowledge on ncRNA-mediated regulation in GIST biology is summarized, with emphasis on tumor progression, therapeutic resistance, and possible clinical relevance.
Georgios Mandrakis, Stavros P. Papadakos, Georgia Levidou et al.· International Journal of Mol...· 0 citations
It is proposed that ncRNAs should not be viewed as alternatives to ctDNA, but as potential functional biomarkers that can link tumor genotype, regulatory state, and clinical phenotype within integrated multi-analyte precision oncology.